Hi ahjay
They have used the term " up to 3 trials" previously, so it may be 3 or possibly fewer I guess. Presumably they'll make the decision based on commercial viability factors in relation to each cancer type. What level of competition, market factors etc.
They did not mention manufacturing facilities as such, rather manufacturing platform, which I take to mean the intellectual property of the manufacturing processes. My take is that the plan is still to outsource the manufacturing of the vaccine to established labs, under a licensing arrangement.
Hi ahjayThey have used the term " up to 3 trials" previously, so...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.005(1.69%) |
Mkt cap ! $421.2M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.0¢ | 28.0¢ | $1.540M | 5.332M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 302190 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 50965 | 2 |
View Market Depth
| Last trade - 16.10pm 06/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |